Characterization of 1′-hydroxymidazolam glucuronidation in human liver microsomes

Drug Metabolism and Disposition

Volumn 36, Issue 2, 2008, Pages 331-338

  Zhu, Bing ^a   Bush, David ^a,b   Doss, George A ^a   Vincent, Stella ^a   Franklin, Ronald B ^a,c   Xu, Shiyao ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b University of Arizona   (United States)

^c ARRAY BIOPHARMA INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA HYDROXYMIDAZOLAM; CYTOCHROME P450 3A; DIPHOSPHATE GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 2B7; HECOGENIN; PROTEIN UGT1A4; PROTEIN UGT2B4; UNCLASSIFIED DRUG; URIDINE DIPHOSPHATE GALACTOSE; 1-HYDROXYMETHYLMIDAZOLAM; CENTRAL NERVOUS SYSTEM AGENTS; DICLOFENAC; DRUG DERIVATIVE; GLUCURONIDE; MIDAZOLAM; RECOMBINANT PROTEIN; SAPOGENIN; URIDINE DIPHOSPHATE GLUCURONIC ACID;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; DRUG STRUCTURE; ENZYME KINETICS; GLUCURONIDATION; HUMAN; HUMAN CELL; LIVER MICROSOME; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; DRUG ANTAGONISM; GENETICS; MALE; METABOLISM; SPRAGUE DAWLEY RAT;

ANIMALS; CENTRAL NERVOUS SYSTEM AGENTS; DICLOFENAC; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; MALE; MICROSOMES, LIVER; MIDAZOLAM; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; SAPOGENINS; URIDINE DIPHOSPHATE GLUCURONIC ACID;

EID: 38749135827     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.017962     Document Type: Article

References (24)

1. Al-Zoughool M and Talaska G (2006) 4-Aminobiphenyl N-glucuronidation by liver microsomes: optimization of the reaction conditions and characterization of the UDP-glucuronosyltransferase isoforms. J Appl Toxicol 26:524-532.
2. Bauer TM, Ritz R, Haberthur C, Ha HR, Hunkeler W, and Sleight AJ (1995) Prolonged sedation due to accumulation of conjugated metabolites of midazolam. Lancet 346:145-147.
3. Burchell B, Brierley CH, and Rance D (1995) Specificity of human UDP-glucuronosyltransferases and xenobiotic glucuronidation. Life Sci 57:1819-1831.
4. Dundee JW, Halliday NJ, Harper KW, and Brogden RN (1984) Midazolam: a review of its pharmacologic properties and therapeutic use. Drugs 28:519-543.
5. Fisher MB, Campanale K, Ackermann BL, Vandenbranden M, and Wrighton SA (2000) In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin. Drug Metab Dispos 28:560-566.
6. Green MD and Tephly TR (1996) Glucuronidation of amines and hydroxylated xenobiotics and endobiotics catalyzed by expressed human UGT1.4 protein. Drug Metab Dispos 24:356-363.
7. Heizmann P, Eckert M, and Ziegler WH (1983) Pharmacokinetics and bioavailability of midazolam in man. Br J Clin Pharmacol 16:43S-49S.
8. 14C-midazolam in humans following oral dosing. Arzneimittelforschung 31:2220-2223.
9. Hirata K, Matsumoto Y, Kurokawa A, Onda M, Shimizu M, Fukuoka M, Hirano M, and Yamamoto Y (2003) Possibility of influence of midazolam sedation on the diagnosis of brain death: concentrations of active metabolites after cessation of midazolam. Yakugaku Zasshi 123:811-815.
10. Houston JB and Kenworthy KE (2000) In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metab Dispos 28:246-254.
11. Huang SM, Temple R, Throckmorton DC, and Lesko LJ (2007) Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Clin Pharmacol Ther 81:298-304.
12. King CD, Rios GR, Green MD, and Tephly TR (2000) UDP- glucuronosyltransferases. Curr Drug Metab 1:143-161.
13. King C, Tang W, Ngui J, Tephly T, and Braun M (2001) Characterization of rat and human UDP-glucuronosyltransferases responsible for the in vitro glucuronidation of diclofenac. Toxicol Sci 61:49-53.
14. 1H NMR: development and potential of a method for natural products analysis. J Nat Prod 68:133-149.
15. Raucy JL and Lasker JM (1991) Isolation of P450 enzymes from human liver. Methods Enzymol 206:557-587.
16. Siddle DW, Faithfull L, Gleave M, Wright P, Lindsay N, and Kohl C (2003) Midazolam is metabolized by UGT1A4 in human hepatocytes and hepatic microsomes. Drug Metab Rev 35 (Suppl 1):55.
17. Sipes IG and Gandolfi AJ (1991) Biotransformation of toxicants, in Casarett and Doull's Toxicology (Amdur MO, Doull J, and Klaassen CD eds) pp 88-126, Pergamon Press, New York.
18. Soars MG, Ring BJ, and Wrighton SA (2003) The effect of incubation conditions on the enzyme kinetics of UDP-glucuronosyltransferases. Drug Metab Dispos 31:762-767.
19. Staines AG, Coughtrie WH, and Burchell B (2004) N-Glucuronidation of carbamazepine in human tissues is mediated by UGT2B7. J Pharmacol Exp Ther 311:1131-1137.
20. Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Bacchi CE, Marsh CL, McVicar JP, Barr DM, and Perkins JD (1994a) Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. J Pharmacol Exp Ther 271:557-566.
21. Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Hartwell PS, Raisys VA, Marsh CL, McVicar JP, Barr DM, et al. (1994b) Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther 271:549-556.
22. Uchaipichat V, Mackenzie PI, Elliot DJ, and Miners JO (2006) Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) "probes" for human UDP-glucuronosyltransferases. Drug Metab Dispos 34:449-456.
23. Wong H, Tong V, Riggs KW, Rurak DW, Abbott FS, and Kumar S (2007) Kinetics of valproic acid glucuronidation: evidence for in vivo autoactivation. Drug Metab Dispos 35:1380-1386.
24. Zhang D, Zhao W, Roongta VA, Mitroka JG, Klunk LJ, and Zhu M (2004) Amide N-glucuronidation of maxipost catalyzed by UDP-glucuronosyltransferase 2B7 in humans. Drug Metab Dispos 32:545-551.